1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108. doi:10.3322/caac.21262.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. doi:10.3322/caac.21492.
3. Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245. doi:10.1177/1073274817729245.
4. Budny A, Kozlowski P, Kaminska M, Jankiewicz M, Kolak A, Budny B et al. [Epidemiology and risk factors of hepatocellular carcinoma]. Pol Merkur Lekarski. 2017;43(255):133-9.
5. Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477-91 e1. doi:10.1053/j.gastro.2018.08.065.
6. Mohammadian M, Allah Bakeshei K, Mohammadian-Hafshejani A. International epidemiology of liver cancer: geographical distribution, secular trends and predicting the future. J Prev Med Hyg. 2020;61(2):E259-E89. doi:10.15167/2421-4248/jpmh2020.61.2.1244.
7. Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am. 2014;23(2):289-311. doi:10.1016/j.soc.2013.10.006.
8. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2. doi:10.1002/hep.24199.
9. Kim SH, Moon DB, Kim WJ, Kang WH, Kwon JH, Jwa EK et al. Preoperative prognostic values of alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr. 2016;5(6):461-9. doi:10.21037/hbsn.2016.11.05.
10. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S et al. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017;93(4):233-42. doi:10.1159/000455957.
11. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-14. doi:10.1016/S0140-6736(18)30010-2.
12. Lu W, Yang C, Du P, Zhang JL, Zhang JC. Expression tendency and prognostic value of TCF21 in hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):1466-70. doi:10.1080/21691401.2019.1601102.
13. Qiu J, Pan G, Li M. Decreased expression of long non-coding LOC285194 predicts tumour progression and poor prognosis of hepatocellular carcinoma after curative hepatectomy. Postgrad Med J. 2020;96(1132):79-83. doi:10.1136/postgradmedj-2019-136905.
14. Chen Y, Yan W, Xie Z, Guo W, Lu D, Lv Z et al. Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer. Mol Clin Oncol. 2021;14(2):36. doi:10.3892/mco.2020.2198.
15. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-58. doi:10.1126/science.1235122.
16. Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505(7483):302-8. doi:10.1038/nature12981.
17. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-9. doi:10.1038/nature12634.
18. Yang C, Wu J, de Heus C, Grigoriev I, Liv N, Yao Y et al. EB1 and EB3 regulate microtubule minus end organization and Golgi morphology. J Cell Biol. 2017;216(10):3179-98. doi:10.1083/jcb.201701024.
19. Bouguenina H, Salaun D, Mangon A, Muller L, Baudelet E, Camoin L et al. EB1-binding-myomegalin protein complex promotes centrosomal microtubules functions. Proc Natl Acad Sci U S A. 2017;114(50):E10687-E96. doi:10.1073/pnas.1705682114.
20. Chang YC, Lin HC, Chiang YH, Chen CG, Huang L, Wang WT et al. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017;34(5):83. doi:10.1007/s12032-017-0944-z.
21. Snuderl M, Kannan K, Pfaff E, Wang S, Stafford JM, Serrano J et al. Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nat Commun. 2018;9(1):2868. doi:10.1038/s41467-018-05029-3.
22. Indelicato E, Nachbauer W, Fauth C, Krabichler B, Schossig A, Eigentler A et al. SYNE1-ataxia: Novel genotypic and phenotypic findings. Parkinsonism Relat Disord. 2019;62:210-4. doi:10.1016/j.parkreldis.2018.12.007.
23. Faraj Shaglouf LH, Ranjpour M, Wajid S, Jain SK. Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression. Protoplasma. 2020;257(1):157-67. doi:10.1007/s00709-019-01423-w.
24. Cho SJ, Yoon C, Lee JH, Chang KK, Lin JX, Kim YH et al. KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2018;24(24):6556-69. doi:10.1158/1078-0432.CCR-17-1679.
25. Chen X, Zhang G, Chen B, Wang Y, Guo L, Cao L et al. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. Biomed Pharmacother. 2019;116:108997. doi:10.1016/j.biopha.2019.108997.
26. Chaplin AK, Hardwick SW, Liang S, Kefala Stavridi A, Hnizda A, Cooper LR et al. Dimers of DNA-PK create a stage for DNA double-strand break repair. Nat Struct Mol Biol. 2021;28(1):13-9. doi:10.1038/s41594-020-00517-x.
27. Qi Z, Yan F, Chen D, Xing W, Li Q, Zeng W et al. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma. Biosci Rep. 2020;40(10). doi:10.1042/BSR20202603.
28. Liu B, Ding Y, Li P, Wang T, He S, Jia Z et al. MicroRNA-219c-5p regulates bladder fibrosis by targeting FN1. BMC Urol. 2020;20(1):193. doi:10.1186/s12894-020-00765-5.
29. Cai X, Liu C, Zhang TN, Zhu YW, Dong X, Xue P. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. J Cell Biochem. 2018;119(6):4717-28. doi:10.1002/jcb.26651.
30. Kim SA, Cho EJ, Lee S, Cho YY, Kim B, Yoon JH et al. Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment. Sci Rep. 2020;10(1):21313. doi:10.1038/s41598-020-78440-w.